T. Olea, I. Castillo, C. Jiménez, J. Díez, J. Bartolomé, M. Santana, M. López-Oliva, E. González, R. Selgas, Carreño
Occult Hepatitis C virus (HCV) infection (OCI) is characterized by the presence of HCV-RNA in liver or in peripheral blood mononuclear cells (PBMC) in the absence of serological markers. HCV infection in kidney transplant (KT) recipients is associated with lower patient and graft survival. However, the relationship between KT outcome and OCI is unknown. Our aim was to determine in KT recipients the prevalence, risk factors for OCI, and its prognostic implications. We tested 149 adults KT recipients for the presence of OCI.
{"title":"Epidemiological and clinical implications in Kidney Transplantation of occult Hepatitis C virus infection","authors":"T. Olea, I. Castillo, C. Jiménez, J. Díez, J. Bartolomé, M. Santana, M. López-Oliva, E. González, R. Selgas, Carreño","doi":"10.17352/ACN.000036","DOIUrl":"https://doi.org/10.17352/ACN.000036","url":null,"abstract":"Occult Hepatitis C virus (HCV) infection (OCI) is characterized by the presence of HCV-RNA in liver \u0000or in peripheral blood mononuclear cells (PBMC) in the absence of serological markers. HCV infection \u0000in kidney transplant (KT) recipients is associated with lower patient and graft survival. However, the \u0000relationship between KT outcome and OCI is unknown. Our aim was to determine in KT recipients the \u0000prevalence, risk factors for OCI, and its prognostic implications. We tested 149 adults KT recipients for the presence of OCI.","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126781365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Tarun, Khichi Garima, Saxena Ashutosh, Goyal Ramakant, Salem Nitasha
Background: Diabetic nephropathy (DN) is one of the commonest etiologies for ESRD. Various studies suggest that diabetic nephropathy occurs due to the accumulation of advanced glycosylated end products (AGEs), the activation of isoforms of protein C kinase, etc. Correlation of renal arterial flow resistance, GFR, and progression towards ESRD in DN is not well narrated in literature. Therefore, the main object of the study was to assess renal arterial flow resistance in patients with DN and to compare it with patients having non-evident diabetic nephropathy.
{"title":"Diabetic Nephropathy – Pathophysiology: An Overview","authors":"S. Tarun, Khichi Garima, Saxena Ashutosh, Goyal Ramakant, Salem Nitasha","doi":"10.17352/ACN.000035","DOIUrl":"https://doi.org/10.17352/ACN.000035","url":null,"abstract":"Background: Diabetic nephropathy (DN) is one of the commonest etiologies for ESRD. Various studies suggest that diabetic nephropathy occurs due to the accumulation of advanced glycosylated end products (AGEs), the activation of isoforms of protein C kinase, etc. Correlation of renal arterial flow resistance, GFR, and progression towards ESRD in DN is not well narrated in literature. Therefore, the main object of the study was to assess renal arterial flow resistance in patients with DN and to compare it with patients having non-evident diabetic nephropathy.","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131365883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Nyhan, Michelle Lucas, D. Sudusinghe, D. Wijayaratne, Chathurika Beligaswatta, N. Gunawansa
Lesch-Nyhan disease is a heritable disorder of purine metabolism. Inheritance is X-linked and the disease occurs almost exclusively in males.
莱施-尼汉病是一种遗传性嘌呤代谢紊乱。遗传是x连锁的，这种疾病几乎只发生在男性身上。
{"title":"Malignant hyperthermia in Lesch-Nyhan disease","authors":"W. Nyhan, Michelle Lucas, D. Sudusinghe, D. Wijayaratne, Chathurika Beligaswatta, N. Gunawansa","doi":"10.17352/ACN.000034","DOIUrl":"https://doi.org/10.17352/ACN.000034","url":null,"abstract":"Lesch-Nyhan disease is a heritable disorder of purine metabolism. Inheritance is X-linked and the disease occurs almost exclusively in males.","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129075274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Wunderlich syndrome; Spontaneous Atraumatic Rupture of the kidney: A case report","authors":"Sudusinghe D, W. D., Beligaswatta C, Gunawansa N","doi":"10.17352/acn.000033","DOIUrl":"https://doi.org/10.17352/acn.000033","url":null,"abstract":"","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122298745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Deterioration of renal function in patients with acute decompensated heart failure (ADHF) influences the prognosis, suggesting that ADHF should be managed as an acute cardiorenal syndrome. Close collaboration between cardiologists and nephrologists is frequently crucial for management of this condition. It is noteworthy that renal congestion promotes worsening renal function (WRF). High-dose loop diuretics can cause WRF, but are often necessary for treatment of congestion, which is the main symptom of ADHF. However, it is controversial whether WRF associated with diuretic therapy actually has a poor prognosis. In this review, we focus on the mechanism of renal congestion related to WRF in patients with ADHF and on the current status of WRF. We also review the use of loop diuretics to treat ADHF and chronic heart failure, as well as the current role of selective vasopressin-2 receptor antagonist therapy.
{"title":"Renal congestion related to worsening renal function in patients with acute decompensated heart failure: Diuretic strategy for acute cardiorenal syndrome","authors":"M. Ohno, Yu Misao, and Hiroshige Ohashi","doi":"10.17352/acn.000031","DOIUrl":"https://doi.org/10.17352/acn.000031","url":null,"abstract":"Deterioration of renal function in patients with acute decompensated heart failure (ADHF) influences the prognosis, suggesting that ADHF should be managed as an acute cardiorenal syndrome. Close collaboration between cardiologists and nephrologists is frequently crucial for management of this condition. It is noteworthy that renal congestion promotes worsening renal function (WRF). High-dose loop diuretics can cause WRF, but are often necessary for treatment of congestion, which is the main symptom of ADHF. However, it is controversial whether WRF associated with diuretic therapy actually has a poor prognosis. In this review, we focus on the mechanism of renal congestion related to WRF in patients with ADHF and on the current status of WRF. We also review the use of loop diuretics to treat ADHF and chronic heart failure, as well as the current role of selective vasopressin-2 receptor antagonist therapy.","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116961190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abbasi Muhammad Tanzeel, Asghar Muhammad Rashid, Bashir Khuram, Hashmi Muhammad Nauman
Hyperuricemia management in chronic kidney disease is a challenging task. We encounter this dilemma on regular basis. Kidney disease patients have wide range (CKD population, Hemodialysis & peritoneal dialysis cohort and renal transplant patients). In clinical practice wide range of opinions exists. This dubious area intrigued us to look into it. Looking into available published data majority of studies are observational and few are randomized control trials. All studies favor that high uric acid level has accelerated effect on CKD progression. Controversy is on its management, whether by treating it we are able to slow down CKD progression or not. Data supports that CKD progression is not slowed down but needs more studies to give conclusive answer. In dialysis and renal transplant patients studies showed inverse relationship of high uric levels with all-cause mortality. However, in peritoneal dialysis data suggests linear relationship of hyperuricemia with mortality. A pro as well as anti-oxidant effect of uric acid has been discussed in literature. Variable cut off for hyperuricemia has been used but more census is on 7 mg/dl. Symptomatic gout defi nitely needs uric acid lowering therapy but in asymptomatic hyperuricemia no conclusion so far. There is paucity of data in maintenance dialysis and renal transplant patients. Review article Hyperuricemia in Renal patients: Treat or not to treat Muhammad Tanzeel Abbasi* Muhammad Rashid Asghar, Khuram Bashir and Muhammad Nauman Hashmi Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan Received: 16 July, 2021 Accepted: 05 August, 2021 Published: 06 August, 2021 *Corresponding author: Dr. Muhammad Tanzeel Abbasi, Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan, Tel: 00923336106372; E-mail:
{"title":"Hyperuricemia in Renal patients: Treat or not to treat","authors":"Abbasi Muhammad Tanzeel, Asghar Muhammad Rashid, Bashir Khuram, Hashmi Muhammad Nauman","doi":"10.17352/acn.000056","DOIUrl":"https://doi.org/10.17352/acn.000056","url":null,"abstract":"Hyperuricemia management in chronic kidney disease is a challenging task. We encounter this dilemma on regular basis. Kidney disease patients have wide range (CKD population, Hemodialysis & peritoneal dialysis cohort and renal transplant patients). In clinical practice wide range of opinions exists. This dubious area intrigued us to look into it. Looking into available published data majority of studies are observational and few are randomized control trials. All studies favor that high uric acid level has accelerated effect on CKD progression. Controversy is on its management, whether by treating it we are able to slow down CKD progression or not. Data supports that CKD progression is not slowed down but needs more studies to give conclusive answer. In dialysis and renal transplant patients studies showed inverse relationship of high uric levels with all-cause mortality. However, in peritoneal dialysis data suggests linear relationship of hyperuricemia with mortality. A pro as well as anti-oxidant effect of uric acid has been discussed in literature. Variable cut off for hyperuricemia has been used but more census is on 7 mg/dl. Symptomatic gout defi nitely needs uric acid lowering therapy but in asymptomatic hyperuricemia no conclusion so far. There is paucity of data in maintenance dialysis and renal transplant patients. Review article Hyperuricemia in Renal patients: Treat or not to treat Muhammad Tanzeel Abbasi* Muhammad Rashid Asghar, Khuram Bashir and Muhammad Nauman Hashmi Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan Received: 16 July, 2021 Accepted: 05 August, 2021 Published: 06 August, 2021 *Corresponding author: Dr. Muhammad Tanzeel Abbasi, Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan, Tel: 00923336106372; E-mail:","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120970045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：